Pharmacoproteomics in drug development

Frank Witzmann, Raymond A. Grant

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The field of proteomics is taking on increased significance as the relevance of investigating and understanding protein expression in disease and drug development is appreciated. Recent advances in proteomics have been driven by the availability of numerous annotated whole-genome sequences and a broad range of technological and bioinformatic developments that underscore the complexity of the proteome. This review briefly addresses some of the various technologies that comprise Expression Proteomics and Functional Proteomics, citing examples where these emerging approaches have been applied to pharmacology, toxicology, and the development of drugs.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalPharmacogenomics Journal
Volume3
Issue number2
DOIs
StatePublished - 2003

Fingerprint

Proteomics
Pharmaceutical Preparations
Proteome
Computational Biology
Toxicology
Genome
Pharmacology
Technology
Proteins

Keywords

  • Drug development
  • Mass spectrometry
  • Protein array
  • Protein interactions
  • Proteomics
  • Toxicology
  • Two-dimensional electrophoresis

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Pharmacoproteomics in drug development. / Witzmann, Frank; Grant, Raymond A.

In: Pharmacogenomics Journal, Vol. 3, No. 2, 2003, p. 69-76.

Research output: Contribution to journalArticle

Witzmann, Frank ; Grant, Raymond A. / Pharmacoproteomics in drug development. In: Pharmacogenomics Journal. 2003 ; Vol. 3, No. 2. pp. 69-76.
@article{9dcd32027ea84b23ab3aaa60de1ab9fa,
title = "Pharmacoproteomics in drug development",
abstract = "The field of proteomics is taking on increased significance as the relevance of investigating and understanding protein expression in disease and drug development is appreciated. Recent advances in proteomics have been driven by the availability of numerous annotated whole-genome sequences and a broad range of technological and bioinformatic developments that underscore the complexity of the proteome. This review briefly addresses some of the various technologies that comprise Expression Proteomics and Functional Proteomics, citing examples where these emerging approaches have been applied to pharmacology, toxicology, and the development of drugs.",
keywords = "Drug development, Mass spectrometry, Protein array, Protein interactions, Proteomics, Toxicology, Two-dimensional electrophoresis",
author = "Frank Witzmann and Grant, {Raymond A.}",
year = "2003",
doi = "10.1038/sj.tpj.6500164",
language = "English",
volume = "3",
pages = "69--76",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pharmacoproteomics in drug development

AU - Witzmann, Frank

AU - Grant, Raymond A.

PY - 2003

Y1 - 2003

N2 - The field of proteomics is taking on increased significance as the relevance of investigating and understanding protein expression in disease and drug development is appreciated. Recent advances in proteomics have been driven by the availability of numerous annotated whole-genome sequences and a broad range of technological and bioinformatic developments that underscore the complexity of the proteome. This review briefly addresses some of the various technologies that comprise Expression Proteomics and Functional Proteomics, citing examples where these emerging approaches have been applied to pharmacology, toxicology, and the development of drugs.

AB - The field of proteomics is taking on increased significance as the relevance of investigating and understanding protein expression in disease and drug development is appreciated. Recent advances in proteomics have been driven by the availability of numerous annotated whole-genome sequences and a broad range of technological and bioinformatic developments that underscore the complexity of the proteome. This review briefly addresses some of the various technologies that comprise Expression Proteomics and Functional Proteomics, citing examples where these emerging approaches have been applied to pharmacology, toxicology, and the development of drugs.

KW - Drug development

KW - Mass spectrometry

KW - Protein array

KW - Protein interactions

KW - Proteomics

KW - Toxicology

KW - Two-dimensional electrophoresis

UR - http://www.scopus.com/inward/record.url?scp=0038312125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038312125&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500164

DO - 10.1038/sj.tpj.6500164

M3 - Article

VL - 3

SP - 69

EP - 76

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 2

ER -